FRANKLIN LAKES, N.J. - BD (Becton, Dickinson and Company) (NYSE: BDX), a prominent global medical technology firm, today announced the appointment of Michael Feld as executive vice president and president of its Life Sciences segment.
Feld, who will also join the company's Executive Leadership Team, is set to assume his new role on August 20, 2024. He fills the position following the retirement of Dave Hickey, who concluded a decade-long tenure with BD last month.
Feld brings to BD a wealth of experience from his time at Veralto, a Danaher (NYSE:DHR) spin-off, where he served as president of Hach, a leader in water quality products.
His background includes multiple senior positions within Danaher, including senior vice president and general manager of Cepheid Europe, as well as the presidency of various Danaher businesses, such as Mammotome, XOS, and Dover (NYSE:DOV) Motion. His expertise lies in strategic planning, quality enhancement, associate development, and cultural progression.
Tom Polen, chairman, CEO, and president of BD, lauded Feld's track record, stating, "Mike's expertise in applying commercial and operational excellence principles to deliver impactful results, coupled with his experience in diagnostic solutions, position him well to lead our Life Sciences segment."
Polen emphasized Feld's role in advancing BD's operational system and driving efficiencies in the Life Sciences team, which aligns with the company's commitment to expanding value for customers and the broader healthcare ecosystem.
In his new capacity, Feld will oversee the BD Life Sciences segment, encompassing Biosciences, Diagnostic Solutions, and Specimen Management.
He is tasked with spearheading the development of innovative solutions that span from discovery to diagnosis, focusing on smart, connected workflows, specimen collection, and diagnostics in new care settings to enhance chronic condition treatment.
Feld's academic credentials include a Bachelor of Science degree from Tulane University and a Master of Business Administration from Northwestern (NASDAQ:NWE) University's Kellogg (NYSE:K) School of Management.
This leadership change is based on a press release statement from BD, a company that aims to improve medical discovery, diagnostics, and care delivery, supporting healthcare professionals through innovative technology and solutions. BD's global presence and its workforce of 70,000 strive to address some of the most pressing global health issues.
InvestingPro Insights
As BD (Becton, Dickinson and Company) welcomes Michael Feld to spearhead its Life Sciences segment, investors and stakeholders are closely monitoring the company's financial health and market position. BD's commitment to innovation and leadership in the medical technology industry is reflected in its financial metrics and strategic directions.
InvestingPro data indicates that BD currently holds a substantial market capitalization of $68.19 billion, underscoring its significant presence in the healthcare sector. The company's P/E ratio stands at 47.16, which, while on the higher side, suggests that investors may expect substantial earnings growth in the future. This is further supported by a gross profit margin of 44.9% over the last twelve months as of Q3 2024, indicating a strong ability to generate revenue over its cost of goods sold.
From an investor's perspective, BD's track record of raising its dividend for 53 consecutive years is a noteworthy InvestingPro Tip, highlighting the company's commitment to returning value to shareholders. Additionally, BD's low price volatility, as noted by another InvestingPro Tip, suggests that the stock could be a stable addition to investment portfolios, especially for those seeking consistency in a turbulent market.
For those interested in deeper analysis and additional insights, InvestingPro offers more tips on BD, including expectations on net income growth and profitability forecasts for the year. There are 11 additional tips available on InvestingPro's BD page, providing investors with a comprehensive understanding of BD's financial outlook and performance.
As BD continues to navigate the healthcare landscape with new leadership and innovative solutions, these financial metrics and insights will remain crucial for assessing the company's trajectory and potential impact on the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.